BACKGROUND: Opioid dependence is a significant public health problem associated with high risk for relapse if treatment is not ongoing. While maintenance on opioid agonists (i.e., methadone, buprenorphine) often produces favorable outcomes, detoxification followed by treatment with the μ-opioid receptor antagonist naltrexone may offer a potentially useful alternative to agonist maintenance for some patients. METHOD: Treatment approaches for making this transition are described here based on a literature review and solicitation of opinions from several expert clinicians and scientists regarding patient selection, level of care, and detoxification strategies. CONCLUSION: Among the current detoxification regimens, the available clinical and scientific data suggest that the best approach may be using an initial 2-4 mg dose of buprenorphine combined with clonidine, other ancillary medications, and progressively increasing doses of oral naltrexone over 3-5 days up to the target dose of naltrexone. However, more research is needed to empirically validate the best approach for making this transition.
BACKGROUND: Opioid dependence is a significant public health problem associated with high risk for relapse if treatment is not ongoing. While maintenance on opioid agonists (i.e., methadone, buprenorphine) often produces favorable outcomes, detoxification followed by treatment with the μ-opioid receptor antagonist naltrexone may offer a potentially useful alternative to agonist maintenance for some patients. METHOD: Treatment approaches for making this transition are described here based on a literature review and solicitation of opinions from several expert clinicians and scientists regarding patient selection, level of care, and detoxification strategies. CONCLUSION: Among the current detoxification regimens, the available clinical and scientific data suggest that the best approach may be using an initial 2-4 mg dose of buprenorphine combined with clonidine, other ancillary medications, and progressively increasing doses of oral naltrexone over 3-5 days up to the target dose of naltrexone. However, more research is needed to empirically validate the best approach for making this transition.
Authors: I Elman; M N D'Ambra; S Krause; H Breiter; M Kane; R Morris; L Tuffy; D R Gastfriend Journal: Drug Alcohol Depend Date: 2001-01-01 Impact factor: 4.492
Authors: Richard J Hamilton; Ruben E Olmedo; Sachin Shah; Oliver L Hung; Mary Ann Howland; Jeanmarie Perrone; Lewis S Nelson; Neal L Lewin; Robert S Hoffman Journal: Acad Emerg Med Date: 2002-01 Impact factor: 3.451
Authors: Adam Bisaga; Maria A Sullivan; Andrew Glass; Kaitlyn Mishlen; Kenneth M Carpenter; John J Mariani; Frances R Levin; Edward V Nunes Journal: J Subst Abuse Treat Date: 2014-01-17
Authors: Maria Sullivan; Adam Bisaga; Martina Pavlicova; C Jean Choi; Kaitlyn Mishlen; Kenneth M Carpenter; Frances R Levin; Elias Dakwar; John J Mariani; Edward V Nunes Journal: Am J Psychiatry Date: 2017-01-10 Impact factor: 18.112
Authors: William J Kowalczyk; Karran A Phillips; Michelle L Jobes; Ashley P Kennedy; Udi E Ghitza; Daniel A Agage; John P Schmittner; David H Epstein; Kenzie L Preston Journal: Am J Psychiatry Date: 2015-03-17 Impact factor: 18.112
Authors: Paolo Mannelli; Li-Tzy Wu; Kathleen S Peindl; Marvin S Swartz; George E Woody Journal: Drug Alcohol Depend Date: 2014-02-15 Impact factor: 4.492
Authors: Dennis P Watson; Krista Brucker; Alan McGuire; Nyssa L Snow-Hill; Huiping Xu; Alex Cohen; Mark Campbell; Lisa Robison; Emily Sightes; Rebecca Buhner; Daniel O'Donnell; Jeffrey A Kline Journal: J Subst Abuse Treat Date: 2019-06-06
Authors: Adam Bisaga; Maria A Sullivan; Andrew Glass; Kaitlyn Mishlen; Martina Pavlicova; Margaret Haney; Wilfrid N Raby; Frances R Levin; Kenneth M Carpenter; John J Mariani; Edward V Nunes Journal: Drug Alcohol Depend Date: 2015-07-08 Impact factor: 4.492
Authors: Joshua D Lee; Edward V Nunes; Patricia Novo Mpa; Genie L Bailey; Gregory S Brigham; Allan J Cohen; Marc Fishman; Walter Ling; Robert Lindblad; Dikla Shmueli-Blumberg; Don Stablein; Jeanine May; Dagmar Salazar; David Liu; John Rotrosen Journal: Contemp Clin Trials Date: 2016-08-10 Impact factor: 2.226
Authors: Vivian F Go; Nguyen Le Minh; Constantine Frangakis; Tran Viet Ha; Carl A Latkin; Teerada Sripaipan; Wendy Davis; Carla Zelaya; Nguyen Phuong Ngoc; Vu Minh Quan Journal: Int J Drug Policy Date: 2013-01-17